A Phase III Multicenter Open Label Randomized Controlled Trial of Cefoxitin versus Piperacillin-Tazobactam as Surgical Antibiotic Prophylaxis in Patients Undergoing Pancreatoduodenectomy
Brief description of study
The purpose of this study is to figure out which commonly used antibiotic, cefoxitin or piperacillin-tazobactam, is better at decreasing the rate of surgical site infections after pancreatoduodenectomy.
Detailed description of study
This study aims to leverage the ACS NSQIP data collection processes and infrastructure in collaboration with the AHPBA to prospectively compare two FDA approved antibiotics used as surgical antibiotic prophylaxis in patients undergoing pancreatoduodenectomy (PD). Specifically, this is a pragmatic, multi-center randomized controlled trial comparing the SCIP-recommended antimicrobial prophylaxis of a second generation cephalosporin, cefoxitin (which is FDA approved for use as a surgical antibiotic prophylaxis), with piperacillin-tazobactam (which is not FDA approved for surgical antibiotic prophylaxis, but is often used in this way off label) in patients undergoing elective PD.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Pancreatic Disease,Pancreatic Cancer
-
Age: 18 years - 100 years
-
Gender: All
Find a site
,
Send a message
Enter your contact details to connect with study team
Primary Contact
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
Please choose between Voice or SMS based delivery of verification code
or